metformin + glyburide + glargine

Metformin + glyburide + glargine is a combination therapy used in the management of type 2 diabetes mellitus. This regimen combines three agents with complementary mechanisms of action to improve glycemic control: - Metformin, a biguanide, decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity. - Glyburide (also known as glibenclamide), a sulfonylurea, stimulates pancreatic beta cells to release more insulin. - Insulin glargine is a long-acting recombinant human insulin analog that provides basal insulin coverage by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. This combination may be prescribed when dual oral therapy (such as metformin plus glyburide) is insufficient for blood sugar control and additional basal insulin support is needed. The primary indication for this regimen is type 2 diabetes mellitus[1][3][4][5].